Lexicon Pharmaceuticals, Inc. (LXRX)
1.42
-0.07
(-4.70%)
USD |
NASDAQ |
Oct 23, 16:00
1.415
0.00 (0.00%)
Pre-Market: 20:00
Lexicon Pharmaceuticals Enterprise Value : 500.44M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 500.44M |
| October 22, 2026 | 531.59M |
| October 21, 2026 | 562.73M |
| October 20, 2026 | 571.63M |
| October 19, 2026 | 558.28M |
| October 16, 2026 | 544.94M |
| October 15, 2026 | 602.78M |
| October 14, 2026 | 580.53M |
| October 13, 2026 | 584.98M |
| October 12, 2026 | 602.78M |
| October 09, 2026 | 616.12M |
| October 08, 2026 | 651.72M |
| October 07, 2026 | 651.72M |
| October 06, 2026 | 647.27M |
| October 05, 2026 | 642.82M |
| October 02, 2026 | 678.42M |
| October 01, 2026 | 678.42M |
| September 30, 2026 | 702.89M |
| September 29, 2026 | 705.11M |
| September 28, 2026 | 714.01M |
| September 25, 2026 | 667.29M |
| September 24, 2026 | 696.21M |
| September 23, 2026 | 785.20M |
| September 22, 2026 | 838.59M |
| September 21, 2026 | 776.30M |
| Date | Value |
|---|---|
| September 18, 2026 | 780.75M |
| September 17, 2026 | 774.08M |
| September 16, 2026 | 767.40M |
| September 15, 2026 | 762.95M |
| September 14, 2026 | 749.61M |
| September 11, 2026 | 758.50M |
| September 10, 2026 | 767.40M |
| September 09, 2026 | 825.25M |
| September 08, 2026 | 860.84M |
| September 04, 2026 | 865.29M |
| September 03, 2026 | 874.19M |
| September 02, 2026 | 865.29M |
| September 01, 2026 | 843.04M |
| August 31, 2026 | 869.74M |
| August 28, 2026 | 887.54M |
| August 27, 2026 | 900.88M |
| August 26, 2026 | 896.44M |
| August 25, 2026 | 909.78M |
| August 24, 2026 | 900.88M |
| August 21, 2026 | 891.99M |
| August 20, 2026 | 838.59M |
| August 19, 2026 | 940.93M |
| August 18, 2026 | 945.38M |
| August 17, 2026 | 909.78M |
| August 14, 2026 | 900.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 159.59B |
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.78M |
| Revenue (Quarterly) | 0.692M |
| Total Expenses (Quarterly) | 32.47M |
| EPS Diluted (Quarterly) | -0.0726 |
| Gross Profit Margin (Quarterly) | 79.62% |
| Profit Margin (Quarterly) | -4.59K% |
| Earnings Yield | -10.77% |
| Normalized Earnings Yield | -10.29 |